NDC-11 (Package) | NDC-9 (Product) (Descending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00310-0201-97 | 00310-0201 | Anastrozole | Arimidex | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Sept. 5, 2006 | Oct. 31, 2013 | No Longer Used | |
00245-0825-30 | 00245-0825 | Everolimus | TORPENZ | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 24, 2024 | In Use | |
00245-0824-30 | 00245-0824 | Everolimus | TORPENZ | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 24, 2024 | In Use | |
00245-0823-30 | 00245-0823 | Everolimus | TORPENZ | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 24, 2024 | In Use | |
00245-0822-30 | 00245-0822 | Everolimus | TORPENZ | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 24, 2024 | In Use | |
00245-0575-01 | 00245-0575 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | June 25, 2021 | In Use | |
00245-0573-01 | 00245-0573 | Isotretinoin | Isotretinoin | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 21, 2021 | In Use | |
00245-0571-01 | 00245-0571 | Isotretinoin | Isotretinoin | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 21, 2021 | In Use | |
00245-0570-01 | 00245-0570 | Isotretinoin | Isotretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 21, 2021 | In Use | |
00187-5526-75 | 00187-5526 | Bexarotene | Targretin | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 1999 | In Use |
Found 10,000 results in 13 milliseconds — Export these results